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CURRENT METHODS OF TREATMENT 
Management of Systemic Lupus Erythematosus 
By WILLIAM D. ROBINSON 
HIS DISCUSSION will reflect certain concepts concerning the nature T of systemic lupus erythematosus and the iduence of agents used in its 
management. First, the diagnosis must be based on adequate clinical and 
laboratory evidence of multiple system involvement, rather than any single 
manifestation or test. Secondly, the disease is a chronic one with fluctuations 
in the level of activity. In the not too distant past, it was usually recognized 
only in its acute, fulminating and often fatal form. With the development of 
more precise methods of diagnosis it has become apparent that such fulminat- 
ing stages are nearly always episodes in a long-term illness with subacute or 
chronic low grade manifestations, and that systemic lupus erythematosus often 
is characterized only by such subacute or chronic activity. In the third place, 
the agents used in management of the disease are essentially suppressive. The 
dramatic effect of adrenal corticosteroids in essence depends on their ability 
to convert the acute fulminating form of the disease to a subacute or chronic 
level of activity. 
The program of management must be highly individualized. There is great 
variation from one patient to another as to the organs and systems which are 
involved, and a fluctuation in the level of activity of the disease in the same 
patient from time to time. Assessment of the activity of the disease must de- 
pend on careful evaluation of various clinical and laboratory findings, as there 
is no single specific and reliable index of activity. 
Before administering adrenocortical steroids or their analogues to patients 
with systemic lupus erythematosus, the physician should attempt to define 
those manifestations of the disease which he intends to suppress with these 
agents. In general, the corticosteroids are effective in suppressing the idamma- 
tory manifestations of the disease, and particularly those that can be at- 
tributed to exudative inflammation. Fever and general toxicity can usually 
be adequately controlled. The erythematous skin rash usually responds in a 
few days. The heat, swelling and redness of involved joints are usually 
promptly controlled., although muscle aching and stiffness may persist to a 
considerable degree. The serosal involvement, manifested as pleuritis, peri- 
carditis, or-less commonly-peritonitis, also responds to steroids. The 
number of granulocytes and platelets in the peripheral blood, if initially de- 
pressed, usually returns to a normal level. Anemia, when present, often does 
not respond to corticosteroid administration unless there is a significant hemo- 
lytic element. With the possible exceptions noted below, ’lupus nephritis” is 
not influenced by steroid therapy. The effect of, these agents on laboratory 
~ 
From the Department of Z n t d  Medicins,  and Rackham Arthritfs Re.wmch Unit 
a grant from the Horace H .  Rackham School of Graduute Studies) Tha (.supported 
Unioersity of Michigan Medical Schod, Ann Arbor, Mich. 
52 1 
ARTHRITIS & RHEUMATISM, VOL. 5, No. 5 (OCXOBW), 1962 
522 WILLSAM D. ROBINSON 
findings is variable. I t  is quite clear that an elevated sedimentation rate, a 
persistently positive L.E. cell test, or an elevation in the titer of antinuclear 
factors or of globulin concentration in the serum do not constitute an indication 
for corticosteroid therapy. The effects of corticotropin, adrenal corticosteroids 
and the synthetic analogues are essentially the same. It is usually advisable 
to avoid the preparations which profoundly influence water and electrolyte 
metabolism. 
Antimalarial drugs were introduced into the treatment of systemic lupus 
erythematosus after it had been demonstrated that these compounds were 
effective in chronic discoid lupus erythematosus. Preparations most frequently 
used are chloroquine, 250 mg. two to three times daily, or hydroxychloroquine, 
200 mg. two to three times daily. The mode of action of these drugs is unknown. 
Experience indicates that they usually are not immediately effective, and they 
certainly cannot be relied upon to suppress acute activity of the disease. They 
are chiefly of value in dealing with the subacute or chronic levels of activity. 
Some workers have felt that the administration of an antimalarial drug re- 
sulted in a significant reduction of dosage of corticosteroids required; however, 
the known spontaneous fluctuations in level of disease activity make it difficult 
to establish this point. If chloroquine or hydroxychloroquine are used, a signif- 
icant effect should not be anticipated until they have been taken for at least 
1 to 2 months, and a period of 6 months’ administration is recommended be- 
fore concluding that these drugs are not of value in the particular patient con- 
cerned. Side reactions to these antimalarials include dermatitis, gastrointestinal 
disturbances, dizziness, psychosis or convulsions, corneal opacities and, rarely, 
bone marrow depression or adenopathy. 
General measures which may be useful in the management of the patient 
with systemic lupus should not be overlooked. Sponging with water or alcohol 
may lower hazardously high fever. Salicylates induce prompt defervescence in 
some patients, and are helpful in relieving the joint symptoms. Not only may 
salicylates be helpful in the acutely ill patient, but their administration can 
control some patients with chronic low grade activity and permit reduction 
in the maintenance dose of corticosteroids. Complicating infection should be 
recognized and treated with appropriate antibiotics. Development of cardiac 
insufficiency is an indication for limitation of activity, digitalization, sodium 
restriction and diuretics as necessary. Severe anemia may require blood trans- 
fusions. 
The basic principle in treating acute fulminating lupus is to use as large a 
dose of corticosteroid as is necessary to suppress the life-threatening manifesta- 
tions of the disease. In the critically ill individual, the effective initial dose 
may be 80 mg. a day or higher of prednisone, or its equivalent with other 
steroid analogues. In individual patients, much larger doses have been re- 
quired to control “acute lupus crises.” After maximal benefit has been achieved, 
the daily dose is gradually reduced. The rapidity with which this is done 
depends on the general condition of the patient, with particular attention to 
the functional status-of the vital organs involved. Once the acute fulminating 
manifestations are suppressed, subsequent management is similar to that of 
the subacute or chronic forms of the disease. 
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The most important precaution in this situation is the necessity for a diligent 
search for a complicating infectious process. Such intercurrent infection is not 
a contraindication to the use of steroids, if the intercuwm infectfm k recog- 
nized and it can be ddvehj ControW by antibiotics or chmwthempy. This 
fact has been particularly well demonstrated in patients with both tuberculosis 
and systemic lupus erythematosus. 
In the seriously, but not critically, ill patent, treatment is initiated with a 
dose of 30 to 40 mg. of prednisone daily, or its equivalent. In less seriously ill 
patients, the initial dose may be in the range of 20 mg. of prednisone daily. 
If after a few days there is no response, this dose is increased in a stepwise 
manner until control of the predetermined manifestations is obtained. After 
maximal benefit has been achieved, the daily dose is gradually reduced, with 
decrements not exceeding 2.5 mg. at each step and with an interval of 5 to 7 
days between steps. Additional measures are brought into play according to 
the individual patient’s manifestations. Every effort is made to keep the 
steroid dosage at the minimal level which will provide reasonable suppression 
of the disease activity. Since many patients manifest a sensitive balance be- 
tween dosage and suppression of disease activity, the decrease in corticosteroid 
dosage is best carried out more slowly than in patients with rheumatoid arth- 
ritis. 
Particularly when dealing with chronic low-grade activity should the physi- 
cian consider whether or not corticosteroids are necessary to control the dis- 
ease manifestations. Many of these patients can be controlled with other 
measures, including antimalarial drugs. Regular use of salicylates is indicated 
for patients in whom musculoskeletal complaints predominate, and physical 
medicine measures may be helpful. Even in patients with chronic low grade 
activity it is important to avoid fatigue and regular afternoon rest periods 
should be advised. The patient should avoid exposure to the sun, since further 
systemic as well as dermal manifestations may develop after such exposure. 
The untoward reactions in the course of corticosteroid therapy are well 
known. Since the dosage of steroids required for the control of systemic 
lupus erythematosus is often higher than in rheumatoid arthritis, such undesir- 
able effects may present considerable difficulty. At times the physician must 
decide whether some degree of activity of the lupus is a greater risk to the 
patient than the potential untoward reaction to the hormones. Particularly 
troublesome problems are presented when new symptoms develop in the pa- 
tient with systemic lupus erythematosus under treatment with corticosteroids. 
These may be due to un untoward reaction to the hormone, indicating a re 
duction in dosage; or due to an increased activity of the lupus, suggesting 
the need for increased dosage; or attributable to an intercurrent process, 
perhaps masked to some extent by the corticosteroids. Careful appraisal of 
aII features of the patient’s illness is required at this point. Sometimes cautious 
reduction in steroid dosage will help to clarify the picture, as the manifesta- 
tions of the primary disease which have just barely been suppressed will 
usually flare if this is done. In other patients, the potential danger of such 
a flare precludes the reduction in dosage. 
The renal complications of systemic lupus erythematosus, when present, re- 
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quire special consideration. Kidney involvement in this disease may simulate 
either the nephrotic syndrome or subacute or chronic glomerulotubular ne- 
phritis, and renal failure is the most common cause of death. There is general 
agreement that the use of adrenal corticosteroids in suppressive dosage, as 
described above, does not influence the course of ‘lupus nephritis.” Although 
other manifestations of the disease may be suppressed by appropriate doses of 
the corticoids, once renal impairment is established it appears to be progressive 
and these patients usually die in uremia. Recently, however, Pollak and his 
associates have reported that improvement of the renal lesion may result 
from large doses of prednisone, 50 to 60 mg. daily, given for a period of 6 
months. These investigators relied heavily on serial renal biopsies as evidence 
of improvement, but also noted improved survival in a small group of patients 
as compared with a previous group of patients who had received only sup- 
pressive doses of adrenal corticosteroids. It may be significant that such im- 
provement of survival was not seen in patients whose blood urea nitrogen 
exceeded 30 mg. per cent at the time of initiation of the large-dose therapy. 
These favorable results have not as yet been confirmed by other observers. 
Until further information is available, the following recommendations can 
be well supported. When systemic lupus erythematosus presents as the ne- 
phrotic syndrome, the therapeutic program should be directed accordingly 
and include the use of adrenocortical steroids in large doses for at least 
several weeks. The use of large doses for several months, as recommended by 
Pollak, Pirani and Kark, appears justified in patients with established kidney 
disease in whom renal function is not severely impaired, provided the patient 
and physician are willing to accept the risks of the induced hyperadrenal 
cortical state over this period of time. If renal function is already severely im- 
paired, such large dose therapy is useless, and may appear to be disastrous. 
In summary, the management of systemic lupus erythematosus is a highly 
individualized proposition. It is not dependent on any single method of treat- 
ment, It is carefully adapted to the needs of the individual patient, taking into 
account the organs and systems involved and the level of disease activity at 
any given time. It requires close medical supervision and the intelligent cooper- 
ation of the patient, as well as alertness on the part of the physician to the 
changes in disease manifestations, to intercurrent complications, and to com- 
plications of the program of management itself. 
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Discussions 
THE DECISION to label a patient “SLE” is ones-such as those which involve the CNS 
a serious responsibility based on clinical (e.g.. pseudo-tumor cerebri or psychiatric 
judgment. Unfortunately, many pieces are symptoms) or large blood vessels (e.g., 
missing from the jigsaw puzzle which makes aortitis). Often one has to temporize until 
up the whole clinical picture. It is -cult new symptoms and signs develop which give 
to be sure about “early” cases or bizarre criteria more acceptable for diagnosis. In 
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many, however, only a presumptive diag- 
nosis may be made even after prolonged 
study. 
This conservative attitude is proper, but 
there is always the nagging thought that if 
one had been willing to “stick one’s neck 
out” a little earlier, the disorder might have 
been managed better in some patients by a 
simple regimen involving small doses of 
steroids and avoidance of possible precipitat- 
ing factors. These are: all unnecessary 
drugs (such as penicillin, sulfanilomide, and 
phenylbutazone), exposure of the hands to 
cold and the body to sun, contact with sens- 
itizing cosmetics and hair dyes (especially 
those containing pma-phenylenediamine ) , 
and household and garden chemicals. 
Patients who wish or expect to become 
pregnant would be told to report as soon 
after conception as possible for frequent 
visits throughout pregnancy and into the 
3rd month of the puerperium. This would 
allow one to catch and vigorously treat with 
large enough doses of steroids the fulminat- 
ing cases which are precipitated during 
the 4th to 8th week post-partum and dur- 
ing the first trimester of pregnancy. These 
acute flare-ups related to pregnancy should 
be treated promptly and effectively with 
steroids to minimize the danger to the health 
of mother and fetus. Other very acute flare- 
ups of SLE may on occasion require heroic 
treatment with up to 1 3  Gm. of hydro- 
cortisone intravenously every 24 hours. Too 
frequently the acutely and very severely ill 
patient with SLE may die suddenly after a 
short period of debilitating illness. Such 
deaths often occur from undertreatment and 
may be prevented by the prompt adminis- 
tration of large doses of hydrocortisone in- 
travenously. When these cases are brought 
under control the dosage must be slightly 
reduced by small decrements until a small 
standard dose is reached-the crisis being 
o v e r 4 1  until the symptoms begin to re- 
cur, at which time the dosage must be 
quickly increased to a sufficient level to 
suppress activity. Activity still has to be 
gauged by trial of therapy. Osler indicates 
that his measurements of serum complement 
levels and antinuclear factors may provide 
a laboratory method of gauging activity, and 
hopefully we look for confirmation of this 
by others. In our experience, antinuclear 
factors have not provided a reliable enough 
index for the individual patient. 
All too often, as in lupus myocardopathy, 
large doses of hydrocortisone or prednisone 
do not work, or if the activity is suppressed, 
the patient dies of disseminated aspergillosis 
of the lungs or some other fungal, viral, or 
bacterial infection. As we get to know more 
about the natural history of the disease, we 
recognize that many patients with SLE have 
a comparatively long life span; and the 
more fortunate ones, a full and useful life. 
The prognosis is particularly good in those 
who develop an SLE-like disease associated 
with exhibition of Apresoline or other drugs, 
provided that the drugs are stopped. On 
the other hand, unless treated, lupus glom- 
erulonephritis is usually fatal. 
As response to treatment is most favorable 
when the blood urea nitrogen has not yet 
climbed to very high levels, it is important 
to recognize the disease early and to treat it 
vigorously when found. Thus, in patients 
who have no evidence of renal disease, the 
urine should be tested each month for pro- 
tein and red blood cells. The patient can 
conveniently test it herself with dipsticks. 
If and when persistent proteinuria develops, 
if the laboratory findings indicate lupus 
glomerulonephritis and if the BUN is not 
higher than about 30 mg/100 ml, then the 
patient should be treated with 50-60 mg. 
prednisone each day for 6 months, as the 
observations of Pollak et al. have now been 
confirmed by Schreiner in Washington, and 
Mackay in Melbourne, Australia. It is still 
difficult, however, to assign definite clinical 
and laboratory criteria which in the in- 
dividual patient will distinguish non-progres- 
sive lupus glomerulitis from progressive lupus 
glomerulonephritis. Thus renal biopsy is 
valuable in deciding who should be treated 
with large doses of prednisone. When this 
is done, close attention must be paid to 
the dietary management. It is important to 
work with the patient and dietitian to in- 
sure a high calcium, high protein intake each 
day while patients are on this regimen, 
This type of dietary regimen is also impor- 
tant in all situations where large amounts 
of steroids are being used. 
It is also important to see that patients 
with lupus, who are debilitated, consume 
a high calorie, high protein diet to prevent 
them going into nutritional bankruptcy. It 
is seldom that one sees lack of absorption of 
foodstuffs in SLE, but this does occasional- 
ly occur; and at  times, even steroids may 
not be absorbed by mouth as evidenced by 
lack of development of ciishingoid features 
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AGE(Yeor) 
AGE 21 (1939) 
AGE 36 (1954) 
AGE 38 (1956)  
AGE 39 (1957) 
AGE 43 (1961) 
EVENT 
BARTHOLIN GLAND INFECTlONtSTS t 
(AND ALL SUBSEQUENT TESTS POSITIVE) 
AFTER PENICILLIN, POLYARTHRITIS 6 MONTHS 
ARTHRALGIA , PE 0 ,  STS t, TPI 0, 
LE CELLS t , JOINT X-RAYS NORMAL 
PE 0, STS t, TPI 0 ,  LE CELLS i 
ASYMPTOMATIC, PE 0 ,  LE CELLS + 
in patients on large doses of prednisone. 
We make the above comments as supple- 
ments to Dr. Robinson’s statements, which 
we regard as admirable. 
ROBERT M. KARK AND VICTOR E. POLLAK 
IT IS A PLEASURE to have the opportunity to 
comment on this excellent description of 
the management of systemic lupus erythem- 
atosus by Dr. Robinson. I was pleased to 
see that he titled the article “management” 
of SLE rather than “treatment.” The term 
treatment implies the use of specific ther- 
apeutic agents while the term management 
embraces the total problem of the handling 
of the patient. SLE serves as a prototype 
of a chronic disease of many years duration 
which may involve almost any structure 
and is punctuated by episodes of acute ill- 
ness interspersed with periods in which the 
process may be relatively quiescent. It is 
important, under these circumstances, to 
give consideration to the patient’s under- 
standing of the disease process and the best 
plan for adapting to it. It encompasses pre- 
ventive measures as well as the forms of 
treatment which may be required for the 
various clinical reflections of activity of the 
process. 
In the management of patients with this 
syndrome, it seems to me important to take 
a somewhat broader concept of diagnosis. 
One possible approach is to consider that 
these individuals have a genetically de- 
termined immunologic abnormality which 
may lead to the formation of auto-antibody 
and delayed sensitivity not only against 
unaltered or relatively slightly altered non- 
foreign antigens but also against substances 
which are not “good” antigens.1 As has 
been pointed out, in SLE one may find a bat- 
tery of antibodies against erythrocyte, leu- 
kocyte and platelet antigens, some of which 
are “poor” antigens; in other individuals, 
against proteins of the clotting complex as 
well as nuclear constituents which also are 
“poor” antigens. In addition, there is de- 
layed sensitization to some of the same 
cellular elements. Our studies in the fol- 
low-up of a large series of healthy individ- 
uals with a biologic false-positive test for 
syphilis (BFP) have indicated that this is 
more than a theoretical concept. We have 
seen individuats who have developed, in 
addition to the BFP reaction, L.E. cells 
and in whom there has been no clinical 
illness except following the administration 
of certain therapeutic agents. In particular, 
we have seen two such individuals whose 
only clinical evidence of the underlying 
abnormality has been the development of 
a polyarthritis of several months duration 
following, in one instance, penicillin, (fig. 
1 )  and in the other, aureomycin. After re- 
covery from the polyarthritis, these patients 
have remained clinically well although they 
continue to show the BFP reaction as well 
as L.E. cells. This implies that it is important 
to recognize the “latent” state of this syn- 
drome, if one may use that term, in order 
to prevent as far as possible those situations 
which may precipitate disease activity, such 
as the administration of drugs and exposure 
to sunlight. 
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In any chronic disease which NI~S an 
intermittent course of activity, such as SLE, 
it is important to recognize that when an 
acute episode of illness occurs it may be 1) 
due to activity of the underlying disease 
process, 2) represent a complication of ther- 
apy, or 3) may be a totally unrelated ill- 
ness. In a disease such as SLE in which t is-  
sue damage in almost any structure may de- 
velop and mimic almost any other disease 
process involving that area, this concept 
becomes of practical importance in manage- 
ment. 
In regard to the use of steroids in the 
treatment of SLE, I would agree entirely 
with Dr. Robinson’s approach that signif- 
icant involvement should be present be- 
fore embarking on the administration of 
steroid hormones. I think it is important for 
the physician to pick one hormone which 
does not have striking effects in terms of 
salt and water retention and become 
thoroughly familiar with the clinical use 
of that hormone in the management of these 
patients. 
In regard to certain specific points in the 
discussion, I believe that caution should be 
exercised in the use of chIoroquine. In most 
instances the potential benefit from the use of 
this drug is not great enough to run the 
risk of the serious toxic effects which may 
ensue after long-term, high-dosage adminis- 
tration. We have seen irreparable ocular 
damage occur from the administration of 
500 mg. of chloroquine over a period of 
6 months. It is our feeling that this dosage 
should not be given for longer than 1 month, 
following which the maximum daily dose 
should be no greater than 250 mg. 
In terms of general measures useful in 
the management of the patient, I think it 
is important to point out that many phy- 
sicians do not explain the nature of the dis- 
ease process in the proper fashion to the 
patient and as a result many of them have 
very serious emotional reactions. This is 
particularly true since on their own they 
often cousult some of the past literature 
which states that the disease is inevitably 
fatal. There is one other comment under 
general measures in regard to transfusions. 
Since these patients do respond immunologi- 
cally to exposure to “poor” antigens, there is 
a greater risk than in the normal individual 
of transfusion reactions to some of the 
erythrocyte iso-antigens which do not ordi- 
~ ~ i l y  evoke an antibody response. 
Although there has been considerable 
discussion in the literature of the need for 
extremely high dosage of steroids in acute 
fulminating lupus, we have rarely seen an 
individual in whom the important manifesta- 
tions of the disease could not be controlled 
with 60 mg. of prednisone as the initial 
dose. High dosage of steroids over prolonged 
periods should certainly be avoided because 
of the serious catabolic effects of these hor- 
mones. 
In terms of preventive measures, Dr. 
Robinson mentions avoiding exposure to the 
sun. In our experience, even more important 
is the avoidance of any unnecessary medica- 
tions because of the wide variety of drugs 
whose administration has been followed by 
acute activity of the disease. 
The problem of management of the r e d  
involvement is difficult, but it has been OUT 
feeling for many years that any evidence of 
renal involvement should be aggressively 
followed and treated. We have seen evidence 
of improvement in patients started on steroid 
therapy when their BUN was above 30 mg. 
per cent. We have also seen patients who 
had clear evidence clinically and on biopsy 
of renal involvement and who, for one reason 
or other, were not treated with steroids and 
whose disease process seemed to remain 
static from the functional point of view over 
several years. Since the renal lesions are so 
uniformly progressive, however, and end 
fatally, I think they should be treated in 
most instances with steroids, even though 
there is evidence of renal functional im- 
pairment. The untoward effects of the ster- 
oids in terms of their catabolic effect can 
be counterbalanced to some degree by regu- 
lating the dietary intake of protein and by 
the use of anabolic steroids. We have r e  
cently seen a patient who was followed in 
another hospital for 3 years with biopsy 
proof of renal lupus without significant 
evidence of advancing renal insuf3ciency 
even though no steroids were administered 
over this period of time. Following a preg- 
nancy, she had an acute exacerbation of the 
nephritis with complete suppression of urine 
flow. Renal biopsy showed extensive changes 
in the glomeruli with widespread fibrinoid 
deposits and hematoxylin bodies. During 3 
weeks she was anuric and two dialyses were 
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necessary. With the use of anabolic steroids 
and other measures during this period the 
BUN did not rise more than 10 mg. per cent 
daily, even though the patient was receiv- 
ing 40-60 mg. of prednisone. After 3 weeks 
she began to secrete urine and a second 
biopsy showed striking improvement in the 
glomerular lesions. There is no doubt that 
one of the important needs is a better means 
of evaluating the degree of activity of the 
renal lesions. Dr. Stevens, working in our 
laboratory, has some preliminary data sug- 
gesting that in the active period there may 
be a greater amount of gammaglobulin in 
the urinary protein. Dr. Townes and Dr. 
Osler are also studying this problem from 
the point of view of quantitation of anti- 
nuclear antibody in the serum along with 
complement determinations. 
Also important in the follow-up of these 
patients is frequent examinations of the 
urine so that the early evidences of renal 
nephritis may be recognized, and the care- 
ful follow-up of these patients during and 
in the period following pregnancy. In this 
way the onset of fulminating activity, which 
may occur particularly in the post-partum 
period, may be recognized early and proper 
steroid therapy outlined. 
One other thing that is of importance in 
the following of patients with SLE and which 
may relate to their proper treatment is to 
be on the look-out for the development of 
other auto-immune diseases. We have seen 
several instances of the gradual onset of 
hypothyroidism with the typical changes in 
the thyroid of Hashimoto’s disease. 
In summary, it is our feeling that if this 
syndrome is recognized early and the pa- 
tients are carefully followed with all of the 
available preventive measures being taken, 
the results of their management can, in a 
large percentage of instances, be quite suc- 
cussful and the patients enabled to lead a 
full and useful life. 
A. MCGEHEE HARVEY 
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